Table 1.
Demographics and clinical characteristics.
| Variable | Training/Validating set | Testing set | ||||
|---|---|---|---|---|---|---|
| MVI−(n = 41) | MVI+(n = 47) | p values* | MVI−(n = 13) | MVI+(n = 10) | p values* | |
| Age | ||||||
| 0, ≤50 years | 8(19.5) | 21(44.7) | 3(23.1) | 0(0) | ||
| 1, >50 years | 33(80.5) | 26(55.4) | 0.012 | 10(76.9) | 10(100) | 0.103 |
| Sex | ||||||
| 0, Female | 5(12.2) | 6(12.8) | 1(7.7) | 1(10) | ||
| 1, Male | 36(87.8) | 41(87.2) | 0.936 | 12(92.3) | 9(90) | 0.846 |
| Hepatitis virus infection (HBV/HCV) | ||||||
| 0, absent | 7(17.1) | 8(17.0) | 4(30.8) | 3(30) | ||
| 1, present | 34(82.9) | 39(83.0) | 0.995 | 9(69.2) | 7(70) | 0.968 |
| Liver cirrhosis | ||||||
| 0, absent | 26(63.4) | 22(46.8) | 6(46.2) | 3(30) | ||
| 1, present | 15(36.6) | 25(53.2) | 0.119 | 7(53.8) | 7(70) | 0.722 |
| AFP | ||||||
| 0, ≤20 µg/L (0–7.5) | 17(41.5) | 19(40.4) | 3(23.1) | 2(20) | ||
| 1, ≤400 µg/L (0–7.5) | 11(26.8) | 9(19.2) | 4(30.8) | 2(20) | ||
| 2, >400 µg/L (0–7.5) | 13(31.7) | 19(40.4) | 0.597 | 6(46.1) | 6(40) | 0.785 |
| WBC | ||||||
| 0, ≤10 × 109/L | 38(92.7) | 42(89.4) | 11(84.6) | 9(90) | ||
| 1, >10 × 109/L | 3(7.3) | 5(10.6) | 0.719 | 2(15.4) | 1(10) | 0.704 |
| Neutrophil | ||||||
| 0, ≤6.3 × 10/L | 37(90.2) | 40(85.1) | 11(84.6) | 9(90) | ||
| 1, >6.3 × 109/L | 4(9.8) | 7(14.9) | 0.467 | 2(15.4) | 1(10) | 0.704 |
| RBC | ||||||
| 0, ≤3.8a/4b × 109/L | 9(21.9) | 5(10.6) | 2(15.4) | 4(40) | ||
| 1, >3.8a/4b × 109/L | 32(78.1) | 42(89.4) | 0.148 | 11(84.6) | 6(60) | 0.393 |
| Hb | ||||||
| 0, ≤128 g/L | 13(31.7) | 15(32.0) | 3(23.1) | 2(20) | ||
| 1, >128 g/L | 28(68.3) | 32(68.0) | 0.983 | 10(76.9) | 8(80) | 1 |
| PLT | ||||||
| 0, ≤100 × 109/L | 5(12.2) | 4(8.5) | 2(15.4) | 1(10) | ||
| 1, >100 × 109/L | 36(87.8) | 43(91.5) | 0.728 | 11(84.6) | 9(90) | 1 |
| PT | ||||||
| 0, ≤13 s | 40(97.6) | 45(95.7) | 12(92.3) | 8(80) | ||
| 1 >13 s | 1(2.4) | 2(4.3) | 1 | 1(7.7) | 2(20) | 0.807 |
| INR | ||||||
| 0, ≤1.0 | 35(85.4) | 36(76.6) | 11(84.6) | 7(70) | ||
| 1, >1.0 | 6(14.6) | 11(23.4) | 0.299 | 2(15.4) | 3(30) | 0.739 |
| AST | ||||||
| 0, ≤40 U/L | 23(56.1) | 23(48.9) | 7(53.8) | 5(50) | ||
| 1, >40 U/L | 18(44.9) | 24(51.1) | 0.502 | 6(46.2) | 5(50) | 1 |
| ALT | ||||||
| 0, ≤50 U/L | 30(73.2) | 37(78.7) | 9(69.2) | 7(70) | ||
| 1, >50 U/L | 11(26.8) | 10(21.3) | 0.542 | 4(30.8) | 3(30) | 1 |
| DBIL | ||||||
| 0, ≤6.8 µmol/L | 29(70.7) | 34(72.3) | 9(69.2) | 9(90) | ||
| 1, >6.8 µmol/L | 12(29.3) | 13(27.7) | 0.867 | 4(30.8) | 1(10) | 0.492 |
| TBIL | ||||||
| 0, ≤20 µmol/L | 32(78.1) | 31(66.0) | 9(69.2) | 6(60) | ||
| 1, >20 µmol/L | 9(21.9) | 16(34.0) | 0.21 | 4(30.8) | 4(40) | 0.985 |
| ALP | ||||||
| 0, ≤125a/135b U/L | 31(75.6) | 33(70.2) | 11(84.6) | 9(90) | ||
| 1, >125a/135b U/L | 10(24.4) | 14(29.8) | 0.571 | 2(15.4) | 1(10) | 1 |
| Scr | ||||||
| 0, ≤133 µmol/L | 38(92.7) | 45(95.7) | 13(100) | 10(100) | ||
| 1, >133 µmol/L | 3(7.3) | 2(4.3) | 0.661 | 0(0) | 0(0) | / |
| ALB | ||||||
| 0, ≤40 g/L | 16(39.0) | 17(36.2) | 1(7.7) | 3(30) | ||
| 1, >40 g/L | 25(60.1) | 30(63.8) | 0.783 | 12(92.3) | 7(70) | 0.398 |
| Child–Pugh | ||||||
| 0, A | 36(87.8) | 40(85.1) | 12(92.3) | 9(90) | ||
| 1, B/C | 5(12.2) | 7(14.9) | 0.713 | 1(7.7) | 1(10) | 1 |
Unless indicated otherwise, data are numbers with percentages in the parentheses. HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, serum alpha-fetoprotein; WBC, White blood cell; RBC, Red blood cell; Hb, Hemoglobin; PLT, platelet count; PT, prothrombin time; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DBIL, Direct bilirubin; TBIL, total bilirubin; ALP, Alkaline phosphatase; Scr, serum creatinine; ALB, serum albumin. *Chi-square test; afemale; bmale. A value of p ˂ 0·05 was considered statistically significant.